Secondly, there is growing interest in targeting metabolic signaling pathways, including PI3K/AKT/mTOR, AMPK, and HIF-1α, as a therapeutic approach to disrupt the metabolic dependencies of ocular tumors. Here, MTOR is linked to eye neoplasm.